KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pacific Biosciences Of California (PACB) EBITDA (2016 - 2026)

Pacific Biosciences Of California has reported EBITDA over the past 16 years, most recently at -$40.3 million for Q4 2025.

  • For Q4 2025, EBITDA fell 3352.34% year-over-year to -$40.3 million; the TTM value through Dec 2025 reached -$546.3 million, down 76.44%, while the annual FY2025 figure was -$546.3 million, 76.44% down from the prior year.
  • EBITDA for Q4 2025 was -$40.3 million at Pacific Biosciences Of California, down from -$37.9 million in the prior quarter.
  • Over five years, EBITDA peaked at $1.2 million in Q4 2024 and troughed at -$426.1 million in Q1 2025.
  • A 5-year average of -$88.1 million and a median of -$72.8 million in 2022 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: plummeted 6894.56% in 2021 and later surged 101.55% in 2024.
  • Year by year, EBITDA stood at -$70.4 million in 2021, then dropped by 17.67% to -$82.9 million in 2022, then increased by 3.53% to -$80.0 million in 2023, then surged by 101.55% to $1.2 million in 2024, then crashed by 3352.34% to -$40.3 million in 2025.
  • Business Quant data shows EBITDA for PACB at -$40.3 million in Q4 2025, -$37.9 million in Q3 2025, and -$42.0 million in Q2 2025.